Changes in LC cases and deaths in male and female from 2004 to 2018, decomposed by three population-level determinants: population aging, population growth and epidemiological chan... by Ze-Xing Zhang (18074512)

Subjects:

Projected ASIR and ASMR of LC in China over the next 15 years based on the Bayesian APC model. by Ze-Xing Zhang (18074512)

Subjects:

The incidence and mortality data of LC by age group from the Chinese Annual Cancer Registry, 2004–2018. by Ze-Xing Zhang (18074512)

Subjects:

Contribution of changes in population aging, population growth, and age-specific incidence rate to changes in incident cases of LC from 2004 to 2018 in China. by Ze-Xing Zhang (18074512)

Subjects:

A summary of calibration standards (n = 3). by Ewa Paszkowska (21246702)

“…<div><p>Purpose</p><p>Statins are the most commonly used drugs worldwide. Besides a significant decrease in cardiovascular diseases (CVDs) risk, the use of statins is also connected with a broad beneficial pleiotropic effect. …”

The observed MRM reactions. by Ewa Paszkowska (21246702)

“…<div><p>Purpose</p><p>Statins are the most commonly used drugs worldwide. Besides a significant decrease in cardiovascular diseases (CVDs) risk, the use of statins is also connected with a broad beneficial pleiotropic effect. …”

Intra- and inter-day precision and accuracy. by Ewa Paszkowska (21246702)

“…<div><p>Purpose</p><p>Statins are the most commonly used drugs worldwide. Besides a significant decrease in cardiovascular diseases (CVDs) risk, the use of statins is also connected with a broad beneficial pleiotropic effect. …”

Socio-demographic characteristics of key informants (n = 21). by Beshir Bedru Nasir (8218863)

Subjects:

Raw data for HCs. by Beshir Bedru Nasir (8218863)

Subjects:

Pre and post COVID-19 Genexpert tests for TB detection trends over 8 months. by Beshir Bedru Nasir (8218863)

Subjects:

A T-test mean comparison of pre and post COVID-19 differences for selected variables. by Beshir Bedru Nasir (8218863)

Subjects:

Comparison of pre and post COVID-19 TB treatment outcomes. by Beshir Bedru Nasir (8218863)

Subjects:

Treatment outcomes of TB patients on follow-up during pre and post COVID-19. by Beshir Bedru Nasir (8218863)

Subjects:

Raw data for hospitals. by Beshir Bedru Nasir (8218863)

Subjects:

Pre and post COVID-19 GeneXpert tests and results to detect TB cases. by Beshir Bedru Nasir (8218863)

Subjects:

Pre and pot COVID-19 total TB patients on follow-up trends over 8 months. by Beshir Bedru Nasir (8218863)

Subjects:

Raw data. by Beshir Bedru Nasir (8218863)

Subjects:

Number and types of total TB patient on follow-up during pre and post COVID-19. by Beshir Bedru Nasir (8218863)

Subjects:

Pre and post COVID-19 positive test results of TB detection trends over 8 months. by Beshir Bedru Nasir (8218863)

Subjects:

DIP grouping and aggregation system. by Chenxuan Zhu (22622476)

“…</p><p>Results</p><p>From January 2019 to June 2023, total costs for surgical and non-surgical groups decreased by 3.42% and 1.25%, respectively. Drug and surgical costs declined significantly (p < 0.05) in both groups, while consumable costs increased significantly (p < 0.05). …”